BioCryst Income Tax Expense vs Cost of Revenue Analysis

BCRX Stock

USD 4.50 0.08 1.75%

BioCryst Pharmaceuticals financial indicator trend analysis is way more than just evaluating BioCryst Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioCryst Pharmaceuticals is a good investment. Please check the relationship between BioCryst Pharmaceuticals Income Tax Expense and its Cost Of Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

Income Tax Expense vs Cost Of Revenue

Income Tax Expense vs Cost of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioCryst Pharmaceuticals Income Tax Expense account and Cost of Revenue. At this time, the significance of the direction appears to have no relationship.

The correlation between BioCryst Pharmaceuticals' Income Tax Expense and Cost of Revenue is 0.04. Overlapping area represents the amount of variation of Income Tax Expense that can explain the historical movement of Cost of Revenue in the same time period over historical financial statements of BioCryst Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of BioCryst Pharmaceuticals' Income Tax Expense and Cost of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Tax Expense of BioCryst Pharmaceuticals are associated (or correlated) with its Cost of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost of Revenue has no effect on the direction of Income Tax Expense i.e., BioCryst Pharmaceuticals' Income Tax Expense and Cost of Revenue go up and down completely randomly.

Correlation Coefficient

0.04

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Income Tax Expense

Cost Of Revenue

Cost of Revenue is found on BioCryst Pharmaceuticals income statement and represents the costs associated with goods and services BioCryst Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from BioCryst Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioCryst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.At this time, BioCryst Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 1.9 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 324.9 K in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	327.6M	412.7M	428.8M	450.2M
Cost Of Revenue	7.3M	6.6M	6.3M	9.2M

Total Operating Expenses Cost Of Revenue

BioCryst Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Non Currrent Assets Other	Common Stock Total Equity	Short Term Investments	Common Stock	Other Liab	Current Deferred Revenue
Total Assets		0.93	0.9	0.87	-0.63	0.79	0.71	-0.94	0.91	0.75	0.06	0.99	0.95	0.94	0.15	0.52	0.95	0.81	1.0	-0.39	-0.31	0.93	0.64	0.93	-0.66	-0.3
Short Long Term Debt Total	0.93		0.88	0.81	-0.39	0.86	0.91	-0.92	0.79	0.51	-0.01	0.89	0.86	0.99	0.23	0.72	0.99	0.85	0.93	-0.4	-0.26	0.85	0.82	0.84	-0.54	-0.2
Other Current Liab	0.9	0.88		0.95	-0.55	0.9	0.77	-0.94	0.82	0.51	0.26	0.88	0.91	0.87	-0.08	0.58	0.9	0.87	0.88	-0.18	-0.22	0.9	0.76	0.9	-0.64	-0.34
Total Current Liabilities	0.87	0.81	0.95		-0.54	0.89	0.7	-0.95	0.87	0.49	0.19	0.86	0.94	0.81	-0.01	0.61	0.85	0.82	0.86	0.01	-0.14	0.96	0.75	0.96	-0.72	-0.41
Total Stockholder Equity	-0.63	-0.39	-0.55	-0.54		-0.36	-0.07	0.58	-0.61	-0.8	-0.17	-0.68	-0.68	-0.41	0.36	0.27	-0.44	-0.53	-0.61	0.25	0.61	-0.63	0.0	-0.66	0.6	0.43
Property Plant And Equipment Net	0.79	0.86	0.9	0.89	-0.36		0.86	-0.9	0.7	0.28	0.12	0.75	0.83	0.84	0.08	0.72	0.87	0.94	0.79	-0.1	-0.22	0.84	0.89	0.83	-0.59	-0.25
Net Debt	0.71	0.91	0.77	0.7	-0.07	0.86		-0.79	0.53	0.11	0.02	0.64	0.67	0.88	0.28	0.87	0.87	0.81	0.71	-0.2	-0.14	0.67	0.95	0.65	-0.37	-0.13
Retained Earnings	-0.94	-0.92	-0.94	-0.95	0.58	-0.9	-0.79		-0.88	-0.57	-0.06	-0.92	-0.98	-0.92	-0.11	-0.63	-0.95	-0.88	-0.94	0.14	0.28	-0.97	-0.77	-0.97	0.67	0.43
Accounts Payable	0.91	0.79	0.82	0.87	-0.61	0.7	0.53	-0.88		0.77	-0.05	0.92	0.93	0.81	0.04	0.45	0.83	0.63	0.92	-0.22	-0.05	0.93	0.5	0.93	-0.64	-0.34
Cash	0.75	0.51	0.51	0.49	-0.8	0.28	0.11	-0.57	0.77		-0.07	0.81	0.68	0.55	-0.03	-0.1	0.56	0.38	0.76	-0.54	-0.35	0.63	-0.02	0.65	-0.52	-0.2
Non Current Assets Total	0.06	-0.01	0.26	0.19	-0.17	0.12	0.02	-0.06	-0.05	-0.07		0.08	0.05	-0.06	-0.13	-0.09	-0.03	0.16	-0.02	0.2	-0.19	0.0	0.06	0.01	0.0	-0.39
Cash And Short Term Investments	0.99	0.89	0.88	0.86	-0.68	0.75	0.64	-0.92	0.92	0.81	0.08		0.95	0.91	0.09	0.44	0.92	0.77	0.99	-0.41	-0.32	0.92	0.56	0.92	-0.68	-0.31
Common Stock Shares Outstanding	0.95	0.86	0.91	0.94	-0.68	0.83	0.67	-0.98	0.93	0.68	0.05	0.95		0.88	0.05	0.52	0.91	0.82	0.95	-0.16	-0.28	0.99	0.66	0.99	-0.72	-0.44
Non Current Liabilities Total	0.94	0.99	0.87	0.81	-0.41	0.84	0.88	-0.92	0.81	0.55	-0.06	0.91	0.88		0.26	0.71	1.0	0.84	0.95	-0.41	-0.26	0.86	0.79	0.85	-0.53	-0.2
Other Current Assets	0.15	0.23	-0.08	-0.01	0.36	0.08	0.28	-0.11	0.04	-0.03	-0.13	0.09	0.05	0.26		0.46	0.22	0.06	0.16	-0.07	-0.06	0.04	0.24	0.03	0.25	-0.04
Other Stockholder Equity	0.52	0.72	0.58	0.61	0.27	0.72	0.87	-0.63	0.45	-0.1	-0.09	0.44	0.52	0.71	0.46		0.71	0.53	0.53	0.07	0.25	0.55	0.92	0.52	-0.22	-0.1
Total Liab	0.95	0.99	0.9	0.85	-0.44	0.87	0.87	-0.95	0.83	0.56	-0.03	0.92	0.91	1.0	0.22	0.71		0.85	0.96	-0.36	-0.25	0.89	0.8	0.89	-0.57	-0.23
Property Plant And Equipment Gross	0.81	0.85	0.87	0.82	-0.53	0.94	0.81	-0.88	0.63	0.38	0.16	0.77	0.82	0.84	0.06	0.53	0.85		0.8	-0.25	-0.52	0.81	0.78	0.81	-0.59	-0.24
Total Current Assets	1.0	0.93	0.88	0.86	-0.61	0.79	0.71	-0.94	0.92	0.76	-0.02	0.99	0.95	0.95	0.16	0.53	0.96	0.8		-0.41	-0.3	0.93	0.63	0.93	-0.66	-0.27
Short Term Debt	-0.39	-0.4	-0.18	0.01	0.25	-0.1	-0.2	0.14	-0.22	-0.54	0.2	-0.41	-0.16	-0.41	-0.07	0.07	-0.36	-0.25	-0.41		0.38	-0.1	0.02	-0.11	0.12	-0.54
Non Currrent Assets Other	-0.31	-0.26	-0.22	-0.14	0.61	-0.22	-0.14	0.28	-0.05	-0.35	-0.19	-0.32	-0.28	-0.26	-0.06	0.25	-0.25	-0.52	-0.3	0.38		-0.22	-0.03	-0.25	0.26	0.12
Common Stock Total Equity	0.93	0.85	0.9	0.96	-0.63	0.84	0.67	-0.97	0.93	0.63	0.0	0.92	0.99	0.86	0.04	0.55	0.89	0.81	0.93	-0.1	-0.22		0.68	1.0	-0.76	-0.4
Short Term Investments	0.64	0.82	0.76	0.75	0.0	0.89	0.95	-0.77	0.5	-0.02	0.06	0.56	0.66	0.79	0.24	0.92	0.8	0.78	0.63	0.02	-0.03	0.68		0.66	-0.44	-0.16
Common Stock	0.93	0.84	0.9	0.96	-0.66	0.83	0.65	-0.97	0.93	0.65	0.01	0.92	0.99	0.85	0.03	0.52	0.89	0.81	0.93	-0.11	-0.25	1.0	0.66		-0.77	-0.4
Other Liab	-0.66	-0.54	-0.64	-0.72	0.6	-0.59	-0.37	0.67	-0.64	-0.52	0.0	-0.68	-0.72	-0.53	0.25	-0.22	-0.57	-0.59	-0.66	0.12	0.26	-0.76	-0.44	-0.77		0.1
Current Deferred Revenue	-0.3	-0.2	-0.34	-0.41	0.43	-0.25	-0.13	0.43	-0.34	-0.2	-0.39	-0.31	-0.44	-0.2	-0.04	-0.1	-0.23	-0.24	-0.27	-0.54	0.12	-0.4	-0.16	-0.4	0.1

Click cells to compare fundamentals

BioCryst Pharmaceuticals Account Relationship Matchups

BioCryst Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	175.3M	334.7M	588.2M	550M	517.0M	542.8M
Short Long Term Debt Total	84.7M	124.7M	593.2M	741.5M	848.7M	891.1M
Other Current Liab	36.3M	55.6M	72.7M	87.6M	102.9M	108.0M
Total Current Liabilities	92.3M	105.7M	103.7M	105.5M	150.0M	157.5M
Total Stockholder Equity	(840.6M)	(1.0B)	(1.2B)	(1.5B)	(455.5M)	(432.8M)
Property Plant And Equipment Net	7.3M	7.1M	8.7M	15.4M	21.0M	22.0M
Net Debt	(29.5M)	(147.4M)	88.8M	436.7M	736.3M	773.1M
Retained Earnings	(840.6M)	(1.0B)	(1.2B)	(1.5B)	(1.7B)	(1.6B)
Accounts Payable	14.0M	18.7M	27.8M	14.4M	20.9M	21.9M
Cash	114.2M	272.1M	504.4M	304.8M	112.4M	65.7M
Non Current Assets Total	10.9M	10.9M	22.0M	33.5M	21.0M	24.6M
Cash And Short Term Investments	136.2M	300.4M	514.4M	442.4M	390.8M	410.3M
Common Stock Shares Outstanding	115.6M	167.3M	179.1M	185.9M	192.2M	201.8M
Liabilities And Stockholders Equity	(703.6M)	(669.5M)	(512.4M)	(610.0M)	517.0M	542.8M
Non Current Liabilities Total	44.7M	248.3M	591.4M	739.1M	822.5M	863.6M
Other Current Assets	4.4M	5.5M	10.0M	12.6M	19.5M	20.5M
Other Stockholder Equity	(1.6M)	(1.8M)	(2.0M)	(1.9M)	1.2B	1.3B
Total Liab	137.0M	354.0M	695.1M	844.6M	972.5M	1.0B
Property Plant And Equipment Gross	7.3M	7.1M	8.7M	25.0M	19.1M	20.1M
Total Current Assets	164.3M	323.8M	566.1M	516.5M	496.0M	520.8M
Accumulated Other Comprehensive Income	39K	3K	177K	26K	1.3M	1.4M
Short Term Debt	40.0M	31.2M	1.8M	2.4M	26.2M	27.5M
Non Currrent Assets Other	3.6M	3.8M	6.5M	(33.5M)	12.0M	7.6M
Common Stock Total Equity	1.1M	1.5M	1.8M	1.8M	2.1M	2.2M
Short Term Investments	22.1M	28.2M	3.2M	119.5M	278.3M	292.3M
Common Stock	1.5M	1.8M	1.8M	1.9M	2.1M	2.2M
Current Deferred Revenue	2.1M	150K	1.4M	1.2M	1.1M	1.0M
Property Plant Equipment	7.3M	7.1M	15.2M	15.4M	17.7M	18.6M
Other Assets	2.0M	978K	588.2M	550M	632.5M	664.1M
Net Receivables	22.1M	8.6M	29.4M	50.6M	57.0M	59.8M
Inventory	1.6M	7.0M	15.8M	27.5M	28.7M	30.1M
Net Tangible Assets	82.9M	109.3M	(147.0M)	(294.6M)	(265.1M)	(251.9M)
Long Term Debt	41.3M	119.7M	585.5M	733.3M	811.3M	851.8M
Retained Earnings Total Equity	(732.0M)	(840.6M)	(1.0B)	(1.2B)	(1.1B)	(1.0B)
Long Term Debt Total	28.1M	41.3M	119.7M	136.1M	156.5M	164.3M
Capital Surpluse	780.4M	877.3M	1.0B	1.1B	1.3B	745.7M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioCryst Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioCryst Pharmaceuticals' short interest history, or implied volatility extrapolated from BioCryst Pharmaceuticals options trading.

Pair Trading with BioCryst Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with BioCryst Stock

0.69

JNJ

Johnson Johnson Financial Report 18th of July 2024

Pair Corr

Moving against BioCryst Stock

0.72	NUVB	Nuvation Bio Financial Report 2nd of May 2024	Pair Corr
0.48	MRKR	Marker Therapeutics	Pair Corr

The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.

The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether BioCryst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioCryst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocryst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocryst Pharmaceuticals Stock:

How To Invest In BioCryst

Details

Is BioCryst Stock a good investment?

Details

What is BioCryst Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for BioCryst Stock analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	AI Investment Finder Use AI to screen and filter profitable investment opportunities
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios

Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.18)

Revenue Per Share

1.724

Quarterly Revenue Growth

0.174

Return On Assets

(0.12)

Return On Equity

(19.25)

The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioCryst Income Tax Expense vs Cost of Revenue Analysis

Income Tax Expense vs Cost Of Revenue

Income Tax Expense vs Cost of Revenue Correlation Analysis

Correlation Coefficient

Income Tax Expense

Cost Of Revenue

BioCryst Pharmaceuticals fundamental ratios Correlations

BioCryst Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioCryst Pharmaceuticals fundamental ratios Accounts

Pair Trading with BioCryst Pharmaceuticals

Moving together with BioCryst Stock

Moving against BioCryst Stock

Complementary Tools for BioCryst Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Non Current Liabilities Total
Common Stock	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total

Common Stock Shares Outstanding	- 0.98	Retained Earnings
Common Stock	- 0.97	Retained Earnings
Common Stock Total Equity	- 0.97	Retained Earnings
Total Liab	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Total Current Liabilities
Total Current Assets	- 0.94	Retained Earnings